Ensign Peak Advisors »

Sab Biotherapeutics shares owned by Ensign Peak Advisors

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Ensign Peak Advisors from 13F filings

Historical chart of Ensign Peak Advisors investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Ensign Peak Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Ensign Peak Advisors

Quarter filed Position value Share count Share price at filing
2026-03-31 $5.3M 1.4M 3.83

More positions owned by Ensign Peak Advisors

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
JPMorgan Chase & Co. (JPM)
Mastercard Incorporated Cl A (MA)
Eli Lilly & Co. (LLY)
Tesla Motors (TSLA)
Exxon Mobil Corporation (XOM)
Oracle Corporation (ORCL)
Johnson & Johnson (JNJ)

View all positions for Ensign Peak Advisors

Top funds holding Sab Biotherapeutics

Vivo Capital
Perceptive Advisors
Commodore Capital
RA Capital Management
Balyasny Asset Management
Millennium Management
Woodline Partners
Vanguard Capital Management
Sessa Capital IM
Vanguard Group
Boothbay Fund Management
Ameriprise Financial
Ensign Peak Advisors
Soleus Capital Management
Propel Bio Management

View all funds holding Sab Biotherapeutics